- Home
- ABVX vs IRMD Comparison
ABVX vs IRMD Comparison
Compare ABVX & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- IRMD
- Stock Information
- Founded
- ABVX 2013
- IRMD 1992
- Country
- ABVX France
- IRMD United States
- Employees
- ABVX N/A
- IRMD N/A
- Industry
- ABVX
- IRMD Medical/Dental Instruments
- Sector
- ABVX
- IRMD Health Care
- Exchange
- ABVX Nasdaq
- IRMD Nasdaq
- Market Cap
- ABVX 722.3M
- IRMD 737.7M
- IPO Year
- ABVX N/A
- IRMD 2014
- Fundamental
- Price
- ABVX $6.16
- IRMD $59.17
- Analyst Decision
- ABVX Strong Buy
- IRMD Strong Buy
- Analyst Count
- ABVX 7
- IRMD 1
- Target Price
- ABVX $37.86
- IRMD $60.00
- AVG Volume (30 Days)
- ABVX 216.6K
- IRMD 40.7K
- Earning Date
- ABVX 09-09-2024
- IRMD 02-06-2025
- Dividend Yield
- ABVX N/A
- IRMD 1.01%
- EPS Growth
- ABVX N/A
- IRMD 13.16
- EPS
- ABVX N/A
- IRMD 1.46
- Revenue
- ABVX $9,676,417.00
- IRMD $71,305,130.00
- Revenue This Year
- ABVX $31.67
- IRMD $13.29
- Revenue Next Year
- ABVX $759.77
- IRMD $10.76
- P/E Ratio
- ABVX N/A
- IRMD $40.53
- Revenue Growth
- ABVX 100.87
- IRMD 13.23
- 52 Week Low
- ABVX $5.54
- IRMD $40.18
- 52 Week High
- ABVX $17.02
- IRMD $59.31
- Technical
- Relative Strength Index (RSI)
- ABVX 30.30
- IRMD 67.63
- Support Level
- ABVX $5.54
- IRMD $55.36
- Resistance Level
- ABVX $6.46
- IRMD $59.31
- Average True Range (ATR)
- ABVX 0.51
- IRMD 1.65
- MACD
- ABVX -0.04
- IRMD 0.30
- Stochastic Oscillator
- ABVX 30.10
- IRMD 97.69
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.